Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JPMorgan Chase & Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while JPMorgan Chase & Co trades at $337.87 (market cap $901.58B). The key difference: JPMorgan Chase & Co is far larger — about 22.6× Alnylam Pharmaceuticals, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | JPM | |
|---|---|---|
Market Cap | $39.89B | $901.58B |
Sector | Health | Financials |
52-Week High | $491.22 | $339.22 |
52-Week Low | $278.09 | $282.84 |
Enterprise Value | $38.15B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JPMorgan Chase (JPM) trades at $336.47, up 0.3% with a bullish technical signal. The stock shows strong fundamentals with $181.85B revenue and 31.61% net margin in 2025, though Q4 2025 EPS missed expectations. Analyst consensus is Moderate Buy with a $360.38 price target, representing 7% upside. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings on April 14.
JPM offers solid investment potential with strong ROE (17.03%) and consistent earnings beats, but faces risks from geopolitical tensions and cybersecurity threats. The current valuation at 16.11 P/E appears reasonable given the bank's market leadership position. Investors should monitor Q2 2026 earnings results for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
